LJAC
NBIX icon

L.J. Altfest & Co’s Neurocrine Biosciences NBIX Stock Holding History

L.J. Altfest & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,835
Closed -$402K – 368
2025
Q4 		$402K Buy
2,835
+210
+8% +$30.4K 0.04% 248
2025
Q3 		$368K Buy
+2,625
New +$356K 0.04% 260

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L.J. Altfest & Co's NBIX Position: Q1 2026 in Review

L.J. Altfest & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,835 shares — an estimated $402K sold.

L.J. Altfest & Co first reported a position in NBIX in Q3 2025 and held it in 2 quarters. The position peaked at $402K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • L.J. Altfest & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • L.J. Altfest & Co sold 2,835 Neurocrine Biosciences shares in Q1 2026, an estimated $402K.
  • L.J. Altfest & Co first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 2 quarters.
  • L.J. Altfest & Co's Neurocrine Biosciences position peaked at $402K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on L.J. Altfest & Co's 13F filing for Q1 2026, filed 28 Apr 2026.